- Thursday, October 29, 2026
- India +91 7982732466
- U.S +1 217 953 4020
- Info@Shingetsuresearch.com
Global Respiratory Antivirals Market By Disease Type (Upper Respiratory Tract Infections, Influenza, Bronchiolitis, Pneumonia, Measles, Croup, and others), By Drug Class (Neuraminidase Inhibitors, Nucleoside Analogs, Fusion Protein Inhibitors, and Ion Channel Blockers) and By Region (North America, Europe, Asia Pacific, South America, and the Middle East & Africa)-Global Forecast to 2027.
Global Respiratory Antivirals Market Overview:
Antiviral drugs are the type of medication used for the treatment of viral infections. A huge number of antivirals target specific viruses, while a broad-spectrum antiviral is productive in front of a wide range of viruses. Unlike most antibiotics, antiviral drugs do not destroy their target pathogen; instead, they inhibit its development. Antiviral therapy aims to minimize symptoms and infectivity as well as to shorten the duration of illness. Several respiratory viral infections continued to be the most important threat to human health because of the similar clinical symptoms. However, different pathogens, sensitive and rapid diagnosis are needed for early identification of viral with cost-effective monitoring during clinical trials. Most antiviral drugs now available are designed to help deal with HIV, herpes viruses, the hepatitis B & C viruses, influenza A & B viruses, and Covid-19. After that, the development of cost-effective, broad-spectrum antiviral agents is an urgent mission for both virologists and pharmacologists.
Global Respiratory Antivirals Market Insights
The global respiratory antivirals market is expected to gain market growth in the forecast period of 2020-2027. The major factors are the growing demand for viral diagnostics tools, systems, equipment & kits, and vaccinations to prevent viral infection. Additionally, the increasing utilization of different kinds of viral detection kits such as RT-PCR or nucleic acid detection kit and bioanalytical assays. Highly sensitive, reliable, and efficient will spur the global respiratory antivirals industry in the future periods. Furthermore, the increasing incidents of respiratory infections, technological advancement, and increasing health care expenditure are expected to witness remarkable growth of respiratory antivirals. The increasing government initiative and rise in awareness of viral infections among people to treat viral diseases are expected to propel the demand for the respiratory antivirals treatment industry over the forecast period.
Moreover, the upsurge in demand for therapeutics for respiratory illness and antiviral drugs positively impacts the market for respiratory antivirals in the health care & pharmaceutical industry. Furthermore, the rapidly rising R&D activities at the academic and industrial level and growing viral infections fuel the demand for the respiratory antiviral market. The rising awareness towards the availability of vaccinations across the globe acts as a restraint to the market growth of antiviral drugs.
Growth Driver
Most of the antiviral drugs now available and are designed to help deal with viruses such as ebolavirus (EBOV), Hendra virus (HEV), and Nipah virus (NiV) but are of limited use in treating a patient who has already been infected. It is also difficult to successfully deploy them against rapidly mutating viruses, such as influenza and HIV. Due to these increasing disorders, many pharmaceutical industries are stepping forward to develop new DNA-based or plant-based vaccines. Moreover, due to the advantages of large market size, increasing viral illness, and gradual maturity of technology applications, antivirals have attracted various enterprises to the layout. Additionally, the manufacturing process’s surge for a wide range of test kits, such as antibody tests, PCR tests, self-administered, and others, will enhance the demand for antivirals in the healthcare industry.
Disease Type Segmental Analysis
Based on the disease type, the global respiratory antivirals market is segregated into upper respiratory tract infections, influenza, bronchiolitis, pneumonia, measles, croup, and others. The upper respiratory tract infections (RTI) segment is estimated to witness the highest growth over the analysis timeframe due to the rising patient population. It is the most common reason for the doctor visit and resulting in missed school &work.
The influenza segment is poised to witness significant growth over the forecast period due to the rising rate of the flu virus and increases in health care provider visits for acute respiratory illness, including influenza A & B.
Drug Class Segmental Analysis
Based on the drug class, the global respiratory antivirals market is categorized into neuraminidase inhibitors, nucleoside analogs, fusion protein inhibitors, and ion channel blockers. The nucleoside analogs segment is further divided into ribavirin, acyclovir, and others, and the neuraminidase inhibitors segment has been sub-divided into oseltamivir zanamivir and so many others. The neuraminidase inhibitors segment is anticipated to dominate/reduce the global respiratory antiviral treatment market during the forecast period due to increasing illnesses such as influenza A and influenza B and their effectiveness in reducing cases and deaths.
The Nucleoside Analogs segment is poised to witness significant growth over the forecast period, including ribavirin and aciclovir. They effectively prevent hepatocellular carcinoma in hepatitis B with long-term protective effects among chronic hepatitis B patients.
Region Segmental Analysis
By geography, the global respiratory antivirals market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. The Asia Pacific is estimated to project considerable growth over 2020-2026. It is owing to rising patients of viral infections with rising demand for therapeutics, advents in technology, the presence of leading industry players offering innovative products, and increasing healthcare expenditure.
Europe will capture a prominent share of the respiratory antivirals market by 2027. It is due to the continually improving healthcare infrastructure in the region and mounting health care expenditures.
Competitor Analysis
Companies such as GlaxoSmithKline plc, AbbVie; Merck & Co, Johnson & Johnson, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Novartis AG, Takeda Pharmaceutical Company Limited, Pfizer, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan Inc, and AstraZeneca plc are the key players in the global respiratory antivirals market.
Key Stakeholders
- Market research and consulting firms
- Industry associations
- Global respiratory antivirals manufacturing firm
- Research organizations and consulting companies
- Organizations, associations, and alliances related to respiratory antivirals
- Regulatory bodies
- Suppliers
- Retailers
The objective of the Research
- Market modeling begins with identifying a target market where historical data exists. A Market can include prediction problems, economic factors, analyzing customer behavior, and identifying new patterns from past events, which helps our client to have deep dive into the market.
- Product analysis involves examining product features, costs, availability, quality, and other aspects. Product analysis is conducted to understand potential buyers and measure competition in the market.
- Market Trend and Economic Factors Analysis helps assess potential changes to an economy’s inflation rate, taxes, interest rates, exchange rates, trading regulations, and excise duties that can or have a major effect on the target market.
- Market Segmental Analysis defines an in-depth scenario of the target market by grouping consumers into naturally existing created segments of consumers who share similar product preferences or characteristics.
- The geographical mapping approach helps our clients to understand national or international markets because different consumers in different regions have different needs, wants, and cultural characteristics that can specifically target.
Market Modelling
By Disease Type
- Upper Respiratory Tract Infections (URTIs)
- Influenza
- Bronchiolitis
- Croup
- Pneumonia
- Measles
- Others
By Drug Class
- Nucleoside Analogs
- Ribavirin
- Aciclovir
- Neuraminidase Inhibitors
- Zanamivir
- Oseltamivir
- Ion Channel Blockers
- Rimantadine
- Amantadine
- Fusion Protein Inhibitors
- Pavilizumab
By Region
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
Report Content
- Research Strategic Development
- Market Modelling
- Product Analysis
- Market Trend and Economic Factors Analysis
- Market Segmental Analysis
- Geographical Mapping
- Country Wise Segregation
- Research Methodology
- Identification of Target Market
- Data Acquisition
- Refining of Data/ Data Transformations
- Data Validation through Primary Techniques
- Exploratory Data Analysis
- Graphical Techniques/Analysis
- Quantitative Techniques/Analysis
- Visual Result/Presentation
- Executive Summary
- Market Insights
- Supply Chain Analysis
- Economic Factor Analysis
- Drivers
- Trends
- Opportunities
- Challenges
- Technological Landscape
- Competitors & Product Analysis
- Regulatory Framework
- Company market share analysis, 2019
- Porter’s Five forces analysis
- New Investment Analysis
- PESTEL Analysis
- Global Respiratory Antivirals Market Overview
- Market Size & Forecast,2016-2027
- Demand
- By Value (USD Million)
- Consumption
- Demand
- Market Share & Forecast, 2016-2027
- By Disease Type
- Upper Respiratory Tract Infections (URTIs)
- Influenza
- Bronchiolitis
- Croup
- Pneumonia
- Measles
- Others
- By Drug Class
- Nucleoside Analogs
- Neuraminidase Inhibitors
- Ion Channel Blockers
- Fusion Protein Inhibitors
- By Region
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
- By Disease Type
- Market Size & Forecast,2016-2027
- North America Respiratory Antivirals Market Overview
- North America Respiratory Antivirals Market Size & Forecast, 2016-2027
- Demand
- By Value (USD Million)
- Consumption
- Demand
- North America Respiratory Antivirals Market Share & Forecast,2016-2027
- By Disease Type
- Upper Respiratory Tract Infections (URTIs)
- Influenza
- Bronchiolitis
- Croup
- Pneumonia
- Measles
- Others
- By Drug Class
- Nucleoside Analogs
- Neuraminidase Inhibitors
- Ion Channel Blockers
- Fusion Protein Inhibitors
- By Country
- US
- Canada
- Mexico
- Price-Point Analysis
- Manufacturer & Distributor List (Top 5)
- Company Market Share (Top 3-5)
- Economic Impact Study on North America Respiratory Antivirals Market
- By Disease Type
- North America Respiratory Antivirals Market Size & Forecast, 2016-2027
- Europe Respiratory Antivirals Market Overview
- Europe Respiratory Antivirals Market Size & Forecast, 2016-2027
- Demand
- By Value (USD Million)
- Consumption
- Demand
- Europe Respiratory Antivirals Market Share & Forecast,2016-2027
- By Disease Type
- Upper Respiratory Tract Infections (URTIs)
- Influenza
- Bronchiolitis
- Croup
- Pneumonia
- Measles
- Others
- By Drug Class
- Nucleoside Analogs
- Neuraminidase Inhibitors
- Ion Channel Blockers
- Fusion Protein Inhibitors
- By Country
- Germany
- UK
- France
- Italy
- Rest of Europe
- Price-Point Analysis
- Manufacturer & Distributor List (Top 5)
- Company Market Share (Top 3-5)
- Economic Impact Study on Europe Respiratory Antivirals Market
- By Disease Type
- Europe Respiratory Antivirals Market Size & Forecast, 2016-2027
- Asia Pacific Respiratory Antivirals Market Overview
- Asia Pacific Respiratory Antivirals Market Size & Forecast, 2016-2027
- Demand
- By Value (USD Million)
- Consumption
- Demand
- Asia Pacific Respiratory Antivirals Market Share & Forecast, 2016-2027
- By Disease Type
- Upper Respiratory Tract Infections (URTIs)
- Influenza
- Bronchiolitis
- Croup
- Pneumonia
- Measles
- Others
- By Drug Class
- Nucleoside Analogs
- Neuraminidase Inhibitors
- Ion Channel Blockers
- Fusion Protein Inhibitors
- By Country
- China
- India
- Japan
- Australia
- Rest of Asia Pacific
- Price-Point Analysis
- Manufacturer & Distributor List (Top 5)
- Company Market Share (Top 3-5)
- Economic Impact Study on Asia Pacific Respiratory Antivirals Market
- By Disease Type
- Asia Pacific Respiratory Antivirals Market Size & Forecast, 2016-2027
- South America Respiratory Antivirals Market Overview
- South America Respiratory Antivirals Market Size & Forecast, 2016-2027
- Demand
- By Value (USD Million)
- Consumption
- Demand
- South America Respiratory Antivirals Market Share & Forecast,2016-2027
- By Disease Type
- Upper Respiratory Tract Infections (URTIs)
- Influenza
- Bronchiolitis
- Croup
- Pneumonia
- Measles
- Others
- By Drug Class
- Nucleoside Analogs
- Neuraminidase Inhibitors
- Ion Channel Blockers
- Fusion Protein Inhibitors
- By Country
- Brazil
- Argentina
- Rest of South America
- Price-Point Analysis
- Manufacturer & Distributor List (Top 5)
- Company Market Share (Top 3-5)
- Economic Impact Study on South America Respiratory Antivirals Market
- By Disease Type
- South America Respiratory Antivirals Market Size & Forecast, 2016-2027
- Middle East & Africa Respiratory Antivirals Market Overview
- Middle East & Africa Respiratory Antivirals Market Size & Forecast, 2016-2027
- Demand
- By Value (USD Million)
- Consumption
- By Volume (Thousands Unit)
- Middle East & Africa Respiratory Antivirals Market Share & Forecast, 2016-2027
- By Disease Type
- Upper Respiratory Tract Infections (URTIs)
- Influenza
- Bronchiolitis
- Croup
- Pneumonia
- Measles
- Others
- By Drug Class
- Nucleoside Analogs
- Neuraminidase Inhibitors
- Ion Channel Blockers
- Fusion Protein Inhibitors
- By Country
- Saudi Arabia
- UAE
- South Africa
- Rest of Middle East & Africa
- Price-Point Analysis
- Manufacturer & Distributor List (Top 5)
- Company Market Share (Top 3-5)
- Economic Impact Study on Middle East & Africa Respiratory Antivirals Market
- By Disease Type
- Demand
- Middle East & Africa Respiratory Antivirals Market Size & Forecast, 2016-2027
- Competitor Analysis
- Company Description
- Financial Analysis
- Key Products
- Key Management Personnel
- Contact Address
- SWOT Analysis
- Company Profile
- GlaxoSmithKline plc
- AbbVie
- Merck &Co
- Johnson & Johnson
- Bristol-Myers Squibb Company
- Hoffmann-La Roche Ltd
- Novartis AG
- Takeda Pharmaceutical Company Limited
- Pfizer
- Teva Pharmaceutical Industries Ltd
- Sun Pharmaceutical Industries Ltd
- Mylan Inc
- AstraZeneca plc
